Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

7.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.3K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

5.6K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

4.7K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
4.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

8.6K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Generative modeling for RNA splicing prediction and design.

eLife·2026
Same author

Detection of a sequence feature for recursive splicing.

bioRxiv : the preprint server for biology·2026
Same author

Glucose-Fueled Histone Modifications Drive HIV-1 Latency Reversal at Hypoxia.

bioRxiv : the preprint server for biology·2025
Same author

Sources of non-uniform coverage in short-read RNA-Seq data.

bioRxiv : the preprint server for biology·2025
Same author

Generative modeling for RNA splicing predictions and design.

bioRxiv : the preprint server for biology·2025
Same author

Machine learning-optimized targeted detection of alternative splicing.

Nucleic acids research·2024

Related Experiment Video

Updated: May 17, 2025

An In Vitro Assay to Detect tRNA-Isopentenyl Transferase Activity
07:46

An In Vitro Assay to Detect tRNA-Isopentenyl Transferase Activity

Published on: October 8, 2018

6.9K

Incomplete paralog compensation generates selective dependency on TRA2A in cancer.

Amanda R Lee1,2,3, Anna Tangiyan3, Isha Singh3

  • 1Department of Pathology & Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States of America.

Plos Genetics
|May 14, 2025
PubMed
Summary
This summary is machine-generated.

Cancer cells can become dependent on the splicing factor TRA2A when its paralog TRA2B cannot compensate. This vulnerability, arising from disrupted paralog buffering, leads to cell death and offers potential therapeutic targets.

More Related Videos

Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase
10:33

Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase

Published on: October 15, 2018

8.1K
Navigating MARRVEL, a Web-Based Tool that Integrates Human Genomics and Model Organism Genetics Information
09:37

Navigating MARRVEL, a Web-Based Tool that Integrates Human Genomics and Model Organism Genetics Information

Published on: August 15, 2019

9.6K

Related Experiment Videos

Last Updated: May 17, 2025

An In Vitro Assay to Detect tRNA-Isopentenyl Transferase Activity
07:46

An In Vitro Assay to Detect tRNA-Isopentenyl Transferase Activity

Published on: October 8, 2018

6.9K
Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase
10:33

Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase

Published on: October 15, 2018

8.1K
Navigating MARRVEL, a Web-Based Tool that Integrates Human Genomics and Model Organism Genetics Information
09:37

Navigating MARRVEL, a Web-Based Tool that Integrates Human Genomics and Model Organism Genetics Information

Published on: August 15, 2019

9.6K

Area of Science:

  • Molecular Biology
  • Cancer Biology
  • Genetics

Background:

  • Paralogs provide functional redundancy, compensating for each other's loss.
  • This compensatory mechanism is often lost in cancer, creating vulnerabilities.
  • Splicing factors play crucial roles in gene expression regulation.

Purpose of the Study:

  • To investigate the functional relationship between splicing factors TRA2A and TRA2B.
  • To identify cancer-specific dependencies related to paralogous splicing factors.
  • To understand the role of paralog buffering in cancer cell survival.

Main Methods:

  • Comparative analysis of TRA2A and TRA2B function in splicing.
  • Depletion studies of TRA2A in cancer cell lines.
  • Assessment of splicing defects, mitotic errors, and cell viability.
  • Overexpression studies of TRA2B to rescue TRA2A loss phenotypes.

Main Results:

  • TRA2A and TRA2B are redundant activators of alternative and constitutive splicing.
  • A subset of cancer cells exhibit dependency on TRA2A due to impaired paralog buffering.
  • TRA2A depletion in these cells leads to splicing defects, mitotic failure, and cell death.
  • TRA2B overexpression rescues TRA2A loss phenotypes, demonstrating dosage sensitivity.

Conclusions:

  • Dysfunctional paralog buffering in cancer creates selective dependencies on splicing factors like TRA2A.
  • The dosage-dependent relationship between TRA2A and TRA2B highlights a novel vulnerability in cancer.
  • Targeting TRA2A or restoring TRA2B function could be potential therapeutic strategies.